english

Liste des publications

Estupina P, Fontayne A, Barret JM, Kersual N, Dubreuil O, Le Blay M, Pichard A, Jarlier M, Pugnière M, Chauvin M, Chardès T, Pouget JP, Deshayes E, Rossignol A, Abache T, de Romeuf C, Terrier A, Verhaeghe L, Gaucher C, Prost JF, Pèlegrin A, Navarro-Teulon I. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells. Oncotarget. 2017 Feb 24. doi: 10.18632/ oncotarget.15715. [Epub ahead of print]

 

Leconet W, Chentouf M, Du Manoir S, Chevalier C, Sirevnt A, Aït-Arsa I, Busson M, Jarlier M, Radosevic - Robin N, Theillet CG, Chalbos D, Pasquet JM, Pèlegrin A, Larbouret C, Robert B. Therapeutic activity of anti-AXL antibody against triple-negative breast cancer Patient Derived Xenografts and metastasis. Clin Cancer Res. 2016 Dec 6. doi: 10.1158/1078-0432.CCR-16-1316. [Epub ahead of print]

 

Bourgier C, Fenoglietto P, Lemanski C, Ducteil A, Charissoux M, Draghici R, Azria D. Modalities of breast cancer irradiation in 2016: Aims and indications of intensity modulated radiation therapy. Cancer Radiother. 2016 Oct;20(6-7): 572-5. doi: 10.1016/j.canrad.2016.07.067. Epub 2016 Sep 7.

 

Azria D, Bourgier C, Brengues M. One Size Fits All: Does the Dogma Stand in Radiation Oncology? EBioMedicine. 2016 Jul 20. [Epub ahead of print]

 

Planque C, Rajabi F, Grillet F, Finetti P, Bertucci F, Gironella M, Lozano JJ, Beucher B, Giraud J, Garambois V, Vincent C, Brown D, Caillo L, Kantar J, Pelegrin A, Prudhomme M, Ripoche J, Bourgaux JF, Ginestier C, Castells A, Hollande F, Pannequin J, Pascussi JM. Pregnane X-receptor promotes stem cell-mediated colon cancer relapse. Oncotarget. 2016 Jul 18. [Epub ahead of print]

 

Le Clorennec C, Lazrek Y, Dubreuil O, Larbouret C, Poul MA, Mondon P, Melino G, Pelegrin , Chardes T. The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation. Oncotarget. 2016 May 18.  [Epub ahead of print]

 

Azria D, Riou O, Castan F, Nguyen TD, Peignaux K, Lemanski C, Lagrange JL, Kirova Y, Lartigau E, Belkacemi Y, Bourgier C, Rivera S, Noël G, Clippe S, Mornex F, Hennequin C, Kramar A, Gourgou S, Pèlegrin A, Fenoglietto P, Ozsahin EM. Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial. EBioMedicine. 2015 Oct 25; 2 (12):1965-73. eCollection 2015.

 

Bourgier C, Kerns S, Gourgou S, Lemanski C, Gutowski M, Fenoglietto P, Romieu G, Crompton N, Lacombe J, Pèlegrin A, Ozsahin M, Rosenstein B, Azria D. Concurrent or sequential letrozole with adjuvant breast radiotherapy: Final results of the CO-HO-RT phase II randomized trial. Ann Oncol. 2015 Dec 17. pii: mdv602. [Epub ahead of print]

 

Gioia R, Trégoat C, Dumas PY, Lagarde V, Prouzet-Mauléon V, Desplat V, Sirvent A, Praloran V, Lippert E, Villacreces A, Leconet W, Robert B, Vigon I, Roche S, Mahon FX, Pasquet JM. CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia. J Pathol. 2015 Sep;237(1):14-24.  Epub 2015 Jun 4.

 

Bourgier C, Colinge J, Aillères N, Fenoglietto P, Brengues M, Pèlegrin A, Azria D. [Radiomics: Definition and clinical development]. Cancer Radiother. 2015 Oct;19(6-7):532-7.

 

Bourgier C, Charissoux M, Boisselier P, Ducteil A, Azria D. What type of hypofractionated radiotherapy of primary tumours in palliative care? Cancer Radiother. 2015 Oct;19(6-7):442-5.

 

Le Gall M, Crepin R, Neiveyans M, Auclair C, Fan Y, Zhou Y, Marks JD, Pelegrin A, Poul MA. Neutralization of KIT oncogenic signaling in leukemia with antibodies targeting KIT membrane proximal domain 5. Mol Cancer Ther. 2015 Sep 10. [Epub ahead of print]

 

C. Larbouret, N. Gaborit, MA. Poul, A. Pèlegrin, T. Chardès. The HER3/ERBB3 receptor : the dark side of the ERBB planet. Med/Sci. (Paris), 2015, 31, 465-468.

 

Eric Assenat1, David Azria, Caroline Mollevi, Rosine Guimbaud, Nicole Tubiana-Mathieu, Denis Smith, Jean-Pierre Delord, Emmanuelle Samalin, Fabienne Portales, Christel Larbouret, Bruno Robert, Frédéric Bibeau, Jean-Pierre Bleuse, Evelyne Crapez, Marc Ychou, and André Pèlegrin. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial.Oncotarget, Vol. 6, No. 14

 

Gaborit N, Abdul-Hai A, Mancini M, Lindzen M, Lavi S, Leitner O, Mounier L, Chentouf M, Dunoyer S, Ghosh M, Larbouret C, Chardès T, Bazin H, Pèlegrin A, Sela M, Yarden Y.  Examination of HER3 targeting in cancer using monoclonal antibodies. Proc Natl Acad Sci U S A. 2015 Jan 20;112 (3):839-44. doi: 10.1073/ pnas.1423645112.

 

Kersual N, Garambois V, Chardès T, Pouget JP, Salhi I, Bascoul-Mollevi C, Bibeau F, Busson M, Vié H, Clémenceau B, Behrens CK, Estupina P, Pèlegrin A, Navarro-Teulon I. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. MAbs. 2014 Sep 3;6(5): 1314-26. doi: 10.4161/mabs.29316.

 

Thomas G, Chardès T, Gaborit N, Mollevi C, Leconet W, Robert B, Radosevic-Robin N, Penault-Llorca F, Gongora C, Colombo PE, Lazrek Y, Bras-Goncalves R, Savina A, Azria D, Bazin H, Pèlegrin A, Larbouret C. HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget. 2014 Aug 30;5(16):7138-7148.

 

Piron B, Paillas S, Boudousq V, Pèlegrin A, Bascoul-Mollevi C, Chouin N, Navarro-Teulon I, Pouget JP. DNA damage-centered signaling pathways are effectively activated during low dose-rate Auger radioimmunotherapy. Nucl Med Biol. 2014 Feb 6. pii: S0969-8051 (14)00 033-X. doi: 10.1016/j. nucmedbio. 2014.01.012. [Epub ahead of print]

 

Leconet W, Larbouret C, Chardès T, Thomas G, Neiveyans M, Busson M, Jarlier M, Radosevic-Robin N, Pugnière M, Bernex F, Penault-Llorca F, Pasquet JM, Pèlegrin A, Robert B. Preclinical validation of AXL receptor as a target for antibody -based pancreatic cancer immunotherapy. Oncogene. 2013 Nov 18. doi: 10.1038/onc.2013.487. [Epub ahead of print]

 

Lozza C, Navarro-Teulon I, Pèlegrin A, Pouget JP, Vivès E. Peptides in Receptor-Mediated Radiotherapy: From Design to the Clinical Application in Cancers. Front Oncol. 2013 Sep 25;3:247.

 

Lacombe J, Riou O, Solassol J, Mangé A, Bourgier C, Fenoglietto P, Pèlegrin A, Ozsahin M, Azria D. Intrinsic radiosensitivity: Predictive assays that will change the daily practice. Cancer Radiother. 2013 Oct;17(5-6):337-43. doi: 10.1016/j.canrad.2013.07.137. Epub 2013 Aug 30.

 

Boudousq V, Bobyk L, Busson M, Garambois V, Jarlier M, Charalambatou P, Pèlegrin A, Paillas S, Chouin N, Quenet F, Maquaire P, Torgue J, Navarro-Teulon I, Pouget JP. Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using (2) (1) (2)Pb. PLoS One. 2013 Jul 29;8(7):e69613. doi: 10.1371/journal.pone.0069613. Print 2013.

 

Navarro-Teulon I, Lozza C, Pèlegrin A, Vivès E, Pouget JP. General overview of radioimmunotherapy of solid tumors. Immunotherapy. 2013 May;5(5):467-87. doi: 10 22 17 /imt .13. 34. 

 

Paillas S, Boudousq V, Piron B, Kersual N, Bardiès M, Chouin N, Bascoul-Mollevi C, Arnaud FX, Pèlegrin A, Navarro-Teulon I, Pouget JP. Apoptosis and p53 are not involved in the anti-tumor efficacy of 125I-labeled monoclonal antibodies targeting the cell membrane. Nucl Med Biol. 2013 May;40(4):471-80.

 

Lazrek Y, Dubreuil O, Garambois V, Gaborit N, Larbouret C, Le Clorennec C, Thomas G, Leconet W, Jarlier M, Pugnière M, Vié N, Robert B, Monnet C, Bouayadi K, Kharrat H, Mondon P, Pèlegrin A, Chardès T. Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and FoxO1 Phosphorylation. Neoplasia. 2013 Mar;15(3):335-47.

 

Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pèlegrin A. In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption. Neoplasia. 2012 Feb;14(2):121-30.

 

Pouget JP, Navarro-Teulon I, Bardiès M, Chouin N, Cartron G, Pèlegrin A, Azria D. Clinical radioimmunotherapy-the role of radiobiology. Nat Rev Clin Oncol. 2011 Nov 8;8(12):720-34.

Rigo M, Chentouf M, Pèlegrin A, Chardès T. CD4 ligation excludes the Carma1-Bcl10-MALT1 complex from GM1-positive membrane rafts in CD3/CD28 activated T cells. Cell Immunol. 2011;270(1):40-6.

 

Ladjemi MZ, Chardes T, Corgnac S, Garambois V, Morisseau S, Robert B, Bascoul-Mollevi C, Ait Arsa I, Jacot W, Pouget JP, Pelegrin A, Navarro-Teulon I. Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice. Breast Cancer Res. 2011 Feb 4;13(1):R17.

 

Gaborit N, Larbouret C, Vallaghe J, Peyrusson F, Bascoul-Mollevi C, Crapez E, Azria D, Chardes T, Poul MA, Mathis G, Bazin H, Pèlegrin A. Time resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies. J Biol Chem. 2011 Apr 1;286(13):11337-45.

 

Boudousq V, Ricaud S, Garambois V, Bascoul-Mollevi C, Boutaleb S, Busson M, Quenet F, Colombo PE, Bardiès M, Kotzki PO, Navarro-Teulon I, Pèlegrin A, Pouget JP. Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing 125I-Labeled Monoclonal Antibodies. J Nucl Med. 2010  Nov; 51(11):1748-55

 

Chentouf M, Rigo M, Ghannam S, Navarro-Teulon I, Mongrand S, Pèlegrin A, Chardès T. The lipid-modulating effects of a CD4-specific recombinant antibody correlate with ZAP-70 segregation outside membrane rafts. Immunol Lett. 2010 Oct 30;133(2):62-9.

 

Ladjemi MZ, Jacot W, Chardès T, Pèlegrin A, Navarro-Teulon I. Anti-HER2 vaccines: new prospects for breast cancer therapy.Télécharger l'article

 

Santoro L, Boutaleb S, Garambois V, Bascoul-Mollevi C, Boudousq V, Kotzki PO, Pèlegrin M, Navarro-Teulon I, Pèlegrin A, Pouget JP. Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis.  J Nucl Med. 2009 Dec;50(12):2033-41

 

Larbouret C, Robert B, Bascoul-Mollevi C, Penault-Llorca F, Ho-Pun-Cheung A, Morisseau S, Navarro-Teulon I, Mach JP, Pèlegrin A, Azria D. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol. 2010 Jan;21(1):98-103

 

Stork R, Campigna E, Robert B, Mueller D, Kontermann RE. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem. 2009. Sep 18;284(38):25612-9

 

Alvarez-Rueda N, Ladjemi MZ, Behar G, Corgnac S, Pugniere M, Roquet F, Bascoul-Mollevi C, Baty D, Pelegrin A, Navarro-Teulon I. A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy. Vaccine 2009. Jul 30;27(35):4826-33

 

Faruque OM, Le-Nguyen D, Lajoix AD, Vives E, Petit P, Bataille D, Hani el H. Cell-permeable peptide-based disruption of endogenous PKA-AKAP complexes: a tool for studying the molecular roles of AKAP-mediated PKA subcellular anchoring. Am J Physiol Cell Physiol 2009; 296: C306-316.

 

Azria D, Ozsahin M, Kramar A, Peters S, Atencio DP, Crompton NE, Mornex F, Pelegrin A, Dubois JB, Mirimanoff RO, Rosenstein BS. Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res 2008; 14: 6284-6288.

 

Pouget JP, Santoro L, Raymond L, Chouin N, Bardies M, Bascoul-Mollevi C, Huguet H, Azria D, Kotzki PO, Pelegrin M, Vives E, Pelegrin A. Cell Membrane is a More Sensitive Target than Cytoplasm to Dense Ionization Produced by Auger Electrons. Radiat Res 2008; 170: 192-200.

 

Ychou M, Azria D, Menkarios C, Faurous P, Quenet F, Saint-Aubert B, Rouanet P, Pelegrin M, Bascoul-Mollevi C, Guerreau D, Saccavini JC, Mach JP, Artus JC, Pelegrin A. Adjuvant Radioimmunotherapy Trial with Iodine-131-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody F6 F(ab')2 after Resection of Liver Metastases from Colorectal Cancer. Clin Cancer Res 2008; 14: 3487-3493.

 

Kucharczak J, Charrasse S, Comunale F, Zappulla J, Robert B, Teulon-Navarro I, Pelegrin A, Gauthier-Rouviere C. R-Cadherin expression inhibits myogenesis and induces myoblast transformation via Rac1 GTPase. Cancer Res 2008; 68: 6559-6568.

 

Ho-Pun-Cheung, A., Assenat, E., Thezenas, S., Bibeau, F., Rouanet, P., Azria, D., Cellier, D., Grenier, J., Ychou, M., Senesse, P., and opez-Crapez, E. Cyclin D1 gene G870A polymorphism predicts response to neoadjuvant radiotherapy and prognosis in rectal cancer. Int J Radiat Oncol Biol Phys, 2007 Jul 15;68(4):1094-101 .

 

Omlin, A., Amichetti, M., Azria, D., Cole, B. F., Fourneret, P., Poortmans, P., Naehrig, D., Miller, R. C., Krengli, M., Gutierrez Miguelez, C., Morgan, D., Goldberg, H., Scandolaro, L., Gastelblum, P., Ozsahin, M., Dohr, D., Christie, D., Oppitz, U., Abacioglu, U., and Gruber, G. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol, 7: 652-656, 2006.

 

Roncalli, J., Delord, J. P., Galinier, M., Massabuau, P., Lescure, M., Fauvel, J. M., and Azria, D. Bevacizumab in metastatic colorectal cancer: a left intracardiac thrombotic event. Ann Oncol, 17: 1177-1178, 2006.

 

Toledano, A., Garaud, P., Serin, D., Fourquet, A., Bosset, J. F., Breteau, N., Body, G., Azria, D., Le Floch, O., and Calais, G. Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study. Int J Radiat Oncol Biol Phys, 65: 324-332, 2006.

 

Zimmermann, M., Zouhair, A., Azria, D., and Ozsahin, M. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol, 1: 11, 2006.

 

Germain C, Larbouret C, Cesson V, Donda A, Held W, Mach JP, Pèlegrin A, Robert B. MHC class-I-related chain A (MICA) conjugated to anti- tumorantibodies can sensitize tumor cells to specific lysis by NK cells. Clin Cancer Res 2005 11: 7516-22..

Azria D, Larbouret C, Cunat S, Ozsahim M, Gourgou S, Martineau P, Evans D, Romieu G, Pujol P, Pèlegrin A. Letrozole sensitizes Breast Cancer Cells to Ionizing Radiation. Breast Cancer Res 2005 7: R156-R163.

Salhi I, Cambon-Roques S, Lamarre I, Laune D, Molina F, Pugniere M, Pourquier D, Gutowski M, Picard JY, Xavier F, Pèlegrin A, Navarro-Teulon I. The anti-Mullerian hormone type II receptor: Insights into the binding domains recognized by a monoclonal antibody and the natural ligand. Biochem J 2004 379: 785-793.

Garambois V, Glaussel F, Foulquier E, Ychou M, Pugniere M, Luo RX, Bezabeh B, Pèlegrin A. Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers. BMC Cancer 2004 4: 75.

Coelho M, Gauthier P, Pugniere M, Roquet F, Pèlegrin A, Navarro-Teulon I. Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice. Brit J Cancer 2004 90: 2032-2041.

 

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Conception : ID Alizés